Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 2581 AL 2595

Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?

Cunnane SC, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P.

Prostaglandins Leukot Essent Fatty Acids. 2013 Jan;88(1):61-70. doi: 10.1016/j.plefa.2012.04.006. Epub 2012 May 9.

Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria

Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J, Gabelle A, Labauge P, Lehmann S.

J Neurol. 2012 Nov;259(11):2429-33. doi: 10.1007/s00415-012-6520-8. Epub 2012 May 11.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12.

[Synaptic vesicle recycling and Alzheimer's disease]

Xia ZM, Hu YE.

Sheng Li Ke Xue Jin Zhan. 2012 Feb;43(1):5-10.

Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools

Di Carlo M, Giacomazza D, San Biagio PL.

J Phys Condens Matter. 2012 Jun 20;24(24):244102. doi: 10.1088/0953-8984/24/24/244102. Epub 2012 May 18.

[Searching for biomarkers to diagnose dementia]

Yanagisawa K.

Nihon Rinsho. 2012 May;70(5):785-9.

Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease

Spies PE, Verbeek MM, van Groen T, Claassen JA.

Front Biosci (Landmark Ed). 2012 Jun 1;17(6):2024-34. doi: 10.2741/4035.

Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction

Lewczuk P.

J Neural Transm (Vienna). 2012 Jul;119(7):735-7. doi: 10.1007/s00702-012-0836-5.

The development of effective biomarkers for Alzheimer's disease: a review

Henry MS, Passmore AP, Todd S, McGuinness B, Craig D, Johnston JA.

Int J Geriatr Psychiatry. 2013 Apr;28(4):331-40. doi: 10.1002/gps.3829. Epub 2012 Jun 4.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults

Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.

Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003. Epub 2012 Jun 6.

Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease

Tariot P, Salloway S, Yardley J, Mackell J, Moline M.

BMC Res Notes. 2012 Jun 8;5:283. doi: 10.1186/1756-0500-5-283.

Prospective interest of molecular neuroimaging in Alzheimer's disease

Guedj E.

Rev Neurol (Paris). 2013 Jan;169(1):9-13. doi: 10.1016/j.neurol.2012.03.007. Epub 2012 Jun 6.

Dealing with uncertainty: biomarkers for the early detection of Alzheimer's disease

Perneczky R, Kurz A.

Int Psychogeriatr. 2012 Oct;24(10):1533-5. doi: 10.1017/S1041610212001056. Epub 2012 Jun 12.

The exception makes the rule: not all Aβ plaques are created equal

Ringman JM, Teplow DB, Villemagne VL.

Neurology. 2012 Jul 17;79(3):206-7. doi: 10.1212/WNL.0b013e31825fe11f. Epub 2012 Jun 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias